Literature DB >> 27014770

Current status in outpatient parenteral antimicrobial therapy: a practical view.

Francisco Javier Candel1, Agustin Julián-Jiménez, Juan González-Del Castillo.   

Abstract

Outpatient parenteral antimicrobial therapy (OPAT) programs are a current and widely spread trend in clinical practice because of it's a cost-effective option, it's associated with a greater comfort for the patient, a lower risk of nosocomial complications and an important cost saving for the health care system. OPAT is used for treating a wide range of infections, including skin and soft tissue infections, osteoarticular infections, bacteraemia, endocarditis and complex intra-abdominal and urinary tract infections, even in presence of multiresistant microorganisms. Correct choice of antimicrobial agent and adequate patient selection are crucial for reaching therapeutic success and avoiding readmissions, treatment prolongation or treatment-related toxicity. The optimal antimicrobial for OPAT must be highly effective, have a long half-life and an adequate spectrum of action. Ceftriaxone and teicoplanin are currently the most prescribed antibiotics for OPAT, though daptomycin and ertapenem are also on the rise, due to their high efficiency, safety and wide spectrum of action. Antibiotics that are stable at room temperature can be administered through a continuous perfusion, though self-administration is preferable although it requires training of the patient or the caregiver. Factors that are most frequently associated with OPAT failure include advanced age, recent hospitalization and isolation of multiresistant microorganisms.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27014770

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  12 in total

1.  Dalbavancin for outpatient parenteral antimicrobial therapy of skin and soft tissue infections in a returning traveller : Proposal for novel treatment indications.

Authors:  Johannes Mischlinger; Heimo Lagler; Nicole Harrison; Michael Ramharter
Journal:  Wien Klin Wochenschr       Date:  2017-08-03       Impact factor: 1.704

2.  Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.

Authors:  Matteo Rinaldi; Pier Giorgio Cojutti; Eleonora Zamparini; Sara Tedeschi; Nicolò Rossi; Matteo Conti; Maddalena Giannella; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

Review 3.  Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?

Authors:  Ester Steffens; Charlotte Quintens; Inge Derdelinckx; Willy E Peetermans; Johan Van Eldere; Isabel Spriet; Annette Schuermans
Journal:  Infection       Date:  2018-11-15       Impact factor: 3.553

4.  Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

Authors:  Laura Herrera-Hidalgo; Arístides de Alarcón; Luis Eduardo López-Cortes; Rafael Luque-Márquez; Luis Fernando López-Cortes; Alicia Gutiérrez-Valencia; María Victoria Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

5.  Physicochemical stability of voriconazole in elastomeric devices.

Authors:  Harmanjeet Harmanjeet; Syed Tabish R Zaidi; Long Chiau Ming; Troy Wanandy; Rahul P Patel
Journal:  Eur J Hosp Pharm       Date:  2017-04-10

6.  Predictors of Unplanned Hospitalization in Patients Receiving Outpatient Parenteral Antimicrobial Therapy Across a Large Integrated Healthcare Network.

Authors:  Monica Schmidt; Bevin Hearn; Michael Gabriel; Melanie D Spencer; Lewis McCurdy
Journal:  Open Forum Infect Dis       Date:  2017-06-16       Impact factor: 3.835

Review 7.  Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.

Authors:  Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2019-08-26

8.  Efficacy and Cost Comparison of Ertapenem as Outpatient Parenteral Antimicrobial Therapy in Acute Pyelonephritis due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae.

Authors:  V Ramasubramanian; P Murlidharan; S Nambi; S Pavithra; S Puthran; T Petigara
Journal:  Indian J Nephrol       Date:  2018 Sep-Oct

Review 9.  Decalogue for the selection of oral antibiotics for lower respiratory tract infections.

Authors:  R Cantón; J Barberán; M Linares; J M Molero; J M Rodríguez-González-Moro; M Salavert; J González Del Castillo
Journal:  Rev Esp Quimioter       Date:  2022-01-19       Impact factor: 1.553

10.  Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT.

Authors:  Laura Herrera-Hidalgo; Rafael Luque-Márquez; Aristides de Alarcon; Ana Belén Guisado-Gil; Belen Gutierrez-Gutierrez; Maria Dolores Navarro-Amuedo; Julia Praena-Segovia; Juan Manuel Carmona-Caballero; Elena Fraile-Ramos; Alicia Gutierrez-Valencia; Luis Eduardo Lopez-Cortes; Maria Victoria Gil-Navarro
Journal:  J Clin Med       Date:  2022-03-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.